Your browser doesn't support javascript.
loading
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa, Rohann J M; Morton, Gerard; Chung, Hans T; Tseng, Chia-Lin; Cheung, Patrick; Chu, William; Liu, Stanley K; McGuffin, Merrylee; Shahid, Anam; Davidson, Melanie; Ravi, Ananth; Helou, Joelle; Alayed, Yasir; Zhang, Liying; Mamedov, Alexandre; Loblaw, Andrew.
Affiliation
  • Correa RJM; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Morton G; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Chung HT; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Tseng CL; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Cheung P; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Chu W; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Liu SK; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • McGuffin M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Shahid A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Davidson M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Ravi A; Molli Surgical, Princess Margaret Cancer Centre, University of Toronto, Canada.
  • Helou J; Department of Radiation Oncology, University of Toronto, Canada; Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada.
  • Alayed Y; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Zhang L; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Mamedov A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Loblaw A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Department of Health Policy, Measurement and Evaluation, University of Toronto, Canada. Electronic address: andrew.loblaw@sunnybrook.ca.
Radiother Oncol ; 169: 51-56, 2022 04.
Article in En | MEDLINE | ID: mdl-35151715
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy / Radiosurgery Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Radiother Oncol Year: 2022 Type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy / Radiosurgery Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Radiother Oncol Year: 2022 Type: Article Affiliation country: Canada